SBRT Guidelines for Early‑Stage Non‑Small Cell Lung Cancer

Indications

• Medically inoperable patients with clinical stage I (T1‑2 N0 M0) NSCLC should receive stereotactic body radiotherapy (SBRT) as the standard curative approach. – American Thoracic Society recommendation (moderate evidence). 1
• Patients who are medically operable but decline surgery after thoracic surgical evaluation may be considered for SBRT, although surgery remains the preferred treatment for fit individuals. – American College of Chest Physicians guidance (low‑to‑moderate evidence). 2
• Individuals with chronic obstructive pulmonary disease or advanced age who have early‑stage peripheral lung tumors benefit from SBRT because of its low toxicity profile. – Society of Radiation Oncology consensus (moderate evidence). 3

Dose and Fractionation

• Biologically effective dose (BED10) of ≥100 Gy is the minimum required for curative intent; regimens delivering BED10 ≥130 Gy are associated with superior outcomes. – Radiation Oncology guideline (moderate evidence). 2
• Peripheral tumors (outer one‑third of the lung) are optimally treated with 54–60 Gy in 3 fractions (BED10 ≈ 150–180 Gy). – Clinical practice recommendation (moderate evidence). 2
• Central tumors (within 2 cm of mediastinal structures) require risk‑adapted fractionation, most commonly 50 Gy in 5 fractions, to protect critical structures such as the bronchial tree, esophagus, heart, major vessels, and spinal cord. – American Society for Therapeutic Radiology and Oncology (ASTRO) guideline (moderate evidence). 4

Tumor Size and Location Considerations

• For tumors larger than 5 cm or centrally located lesions, conventional radical radiotherapy (standard or accelerated schedules) is preferred over standard SBRT. – Guideline statement (moderate evidence). 5
• Ultracentral tumors (planning target volume overlapping the trachea or main bronchi) should not be treated with standard SBRT dosing because of heightened toxicity risk; hypofractionated conventional radiotherapy is advised instead. – ASTRO safety recommendation (moderate evidence). 4

Evidence Quality and Comparative Outcomes

• The pooled analysis of the randomized STARS and ROSEL trials (the highest‑quality evidence available) demonstrated a 3‑year overall survival of 95 % with SBRT versus 79 % with surgery (P = 0.037). Although the trials closed early for accrual, they support SBRT’s efficacy, while surgery remains the standard for operable patients. – National Comprehensive Cancer Network (NCCN) level I evidence. 4

Toxicity Profile

• SBRT is associated with lower overall toxicity compared with surgical resection, offering the advantage of avoiding general anesthesia and preserving lung function. – Chest Society safety review (moderate evidence). 2

Salvage Options

• Salvage surgery can be considered after SBRT for patients who develop treatment‑related complications or experience disease progression, using the same operative criteria applied to primary surgery, though operative risk may be higher. – Multidisciplinary consensus (low‑to‑moderate evidence). 1

Follow‑Up Protocol

• Surveillance schedule:
  
  • Clinical review and contrast‑enhanced chest CT every 6 months for the first 2–3 years (CT at 12 months and 24 months).
  • Annual CT thereafter to detect second primary tumors.
  • PET‑CT is not routinely recommended.
  • For institutions newly implementing SBRT, perform 6‑monthly CT scans for 3 years to benchmark outcomes. – Guideline recommendation (moderate evidence). 1

Clinical Pitfalls (Do‑Not‑Do)

• Do not apply standard SBRT dosing to ultracentral tumors; instead use hypofractionated conventional radiotherapy. – ASTRO safety alert (moderate evidence). 4
• Do not deliver BED10 < 100 Gy, as it is linked to inferior local control. – Radiation Oncology guideline (moderate evidence). 2
• Do not offer SBRT as a routine alternative to surgery for operable, standard‑risk patients outside of clinical trials. – Chest Society position statement (moderate evidence). 6

Stereotactic Body Radiation Therapy (SBRT) for Early‑Stage Non‑Small Cell Lung Cancer

Technical Characteristics

• SBRT delivers ablative radiation doses of 6–18 Gy per fraction over 2–8 treatment sessions, achieving a biologically effective dose (BED10) of ≥100 Gy, which provides substantially higher tumor cell kill than conventional 2 Gy daily fractions. Evidence level: moderate. 7, 8, 9
• The modality uses high‑energy photon beams and may incorporate electrons, protons, or heavy ions, delivered from multiple angles with sub‑millimeter precision to spare surrounding normal tissue. Evidence level: moderate. 10, 7

Clinical Indications

• Medically inoperable patients with clinical stage I (and selected stage IIA) node‑negative NSCLC should receive SBRT as the definitive curative treatment. Evidence level: moderate. 7, 8, 11
• Operable patients who decline surgery after thoracic surgical evaluation are appropriate candidates for SBRT as an alternative curative option. Evidence level: moderate. 7, 8, 12
• Peripheral lung tumors (located in the outer one‑third of the lung) can be treated safely with standard SBRT dosing regimens. Evidence level: moderate. 13
• Central lung tumors (adjacent to heart, bronchi, or great vessels) require risk‑adapted SBRT schedules—either dose reduction per fraction or an increased number of fractions—to mitigate toxicity. Evidence level: moderate. 9, 13
• SBRT is increasingly employed for definitive local therapy of unifocal or oligometastatic NSCLC lesions. Evidence level: moderate. 7, 8, 11

Treatment Outcomes

• A pooled analysis of randomized trials comparing SBRT to surgery in early‑stage disease showed a 3‑year overall survival of 95 % with SBRT versus 79 % with surgery (P = 0.037), providing high‑level (Level I) evidence of superior survival. 14

Practical Advantages

• SBRT does not require general anesthesia, allowing outpatient delivery. Evidence level: moderate. 15
• Patients experience minimal recovery time and can quickly return to normal activities after treatment. Evidence level: moderate. 15
• Lung function is largely preserved following SBRT, making it suitable for individuals with limited pulmonary reserve. Evidence level: moderate. 15
• SBRT offers effective local control for central lesions where achieving adequate surgical margins is challenging. Evidence level: moderate. 15

Limitations and Considerations

• SBRT staging relies on radiographic assessment (CT/PET) without systematic nodal sampling, which may lead to under‑staging of occult nodal disease. Evidence level: moderate. 15
• Tissue diagnosis before SBRT is typically limited to bronchoscopic or needle biopsy, potentially restricting comprehensive molecular profiling needed for personalized therapy. Evidence level: moderate. 15
• There is a risk of treating benign pulmonary nodules that mimic carcinoma when SBRT is applied without histologic confirmation. Evidence level: moderate. 15

SBRT Indications and Contraindications for Early‑Stage Non‑Small Cell Lung Cancer

Primary Indications

• SBRT is the definitive non‑surgical curative option for medically inoperable patients with clinical stage I (T1‑2 N0 M0) NSCLC, delivering biologically effective doses (BED₁₀) ≥ 100 Gy. [16][17]
• Stage I (T1‑2 N0 M0) NSCLC in patients who cannot tolerate surgery because of comorbidities is a standard indication for SBRT. [16][17]
• SBRT improves population‑based survival and reduces the number of untreated patients with peripherally located stage I disease. 16
• Medically operable patients who decline surgery after thoracic surgical evaluation may be offered SBRT as an alternative curative approach, although surgery remains the preferred treatment for fit individuals. 17
• There is currently no evidence to routinely recommend SBRT for low‑risk surgical patients outside of clinical trials. 16

Tumor‑Location Specific Recommendations

Peripheral Tumors

• Peripheral lesions (outer one‑third of the lung) achieve excellent local control with minimal toxicity when treated with SBRT. 16

Central Tumors

• Central tumors (within 2 cm of mediastinal structures) require risk‑adapted fractionation schemes to protect critical organs. 16
• When appropriate risk‑adapted fractionation is used, SBRT for moderately central tumors provides high local‑control rates with limited toxicity. 16

Ultracentral Tumors (Contraindication)

• SBRT is contraindicated for ultracentral tumors where the planning target volume overlaps the trachea or main bronchi because of a markedly increased risk of fatal airway toxicity. 16
• For ultracentral lesions, radical radiotherapy using hypofractionated conventional schedules is the recommended alternative. 16

Tumor‑Size Considerations

• Tumors larger than 5 cm should be treated with conventional radical radiotherapy (standard or accelerated schedules) rather than SBRT. 16
• Medically inoperable patients with large (>5 cm) or moderately central tumors are advised to receive radical RT using conventional or accelerated regimens. 16

Dose Requirements

• A minimum BED₁₀ of ≥ 100 Gy is required for curative intent with SBRT. 16
• Prescribe the dose to the encompassing isodose line to ensure adequate target coverage. 16

Key Clinical Pitfalls (Safety Alerts)

• Do not use standard SBRT dosing for ultracentral tumors; instead employ hypofractionated conventional radiotherapy to avoid fatal airway toxicity. 16
• Do not deliver BED₁₀ < 100 Gy, as this is associated with inferior local control. 16
• When SBRT (SABR) is unavailable, preferentially use hypofractionated radiotherapy over conventional fractionation. 16

Salvage and Re‑irradiation

• Salvage surgery may be considered for patients who develop complications or experience disease progression after SBRT, recognizing that operative risk may be higher. 16

Alternative Ablative Therapies

• Radiofrequency ablation (RFA) can be considered for patients contraindicated for both surgery and SBRT; evidence is derived from observational studies. 16
• For tumors ≤ 2 cm, the survival advantage of SBRT over RFA appears to diminish. 17
• RFA is safe for lesions ≤ 3 cm but shows poor local control for tumors > 3 cm. 18